BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38660802)

  • 21. FBN1 gene mutation characteristics and clinical features for the prediction of mitral valve disease progression.
    Kühne K; Keyser B; Groene EF; Sheikhzadeh S; Detter C; Lorenzen V; Hillebrand M; Bernhardt AM; Hoffmann B; Mir TS; Robinson PN; Berger J; Reichenspurner H; von Kodolitsch Y; Rybczynski M
    Int J Cardiol; 2013 Sep; 168(2):953-9. PubMed ID: 23176764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acetylsalicylic Acid Reduces Passive Aortic Wall Stiffness and Cardiovascular Remodelling in a Mouse Model of Advanced Atherosclerosis.
    Roth L; Rombouts M; Schrijvers DM; Emini Veseli B; Martinet W; De Meyer GRY
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Macrophage Transitions in Heart Valve Development and Myxomatous Valve Disease.
    Hulin A; Anstine LJ; Kim AJ; Potter SJ; DeFalco T; Lincoln J; Yutzey KE
    Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):636-644. PubMed ID: 29348122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Outcomes of Mitral Valve Repair for Leaflet Prolapse with Advanced versus Mild/Moderate Myxomatous Degeneration.
    Guo Y; Song C; Wu X; Zheng X; Lu J; Fang X; Wang S; Huang X
    Int Heart J; 2018 Nov; 59(6):1288-1295. PubMed ID: 30369571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multi-scale biomechanical remodeling in aging and genetic mutant murine mitral valve leaflets: insights into Marfan syndrome.
    Gould RA; Sinha R; Aziz H; Rouf R; Dietz HC; Judge DP; Butcher J
    PLoS One; 2012; 7(9):e44639. PubMed ID: 22984535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lineage-Specific Induced Pluripotent Stem Cell-Derived Smooth Muscle Cell Modeling Predicts Integrin Alpha-V Antagonism Reduces Aortic Root Aneurysm Formation in Marfan Syndrome Mice.
    Nakamura K; Dalal AR; Yokoyama N; Pedroza AJ; Kusadokoro S; Mitchel O; Gilles C; Masoudian B; Leipzig M; Casey KM; Hiesinger W; Uchida T; Fischbein MP
    Arterioscler Thromb Vasc Biol; 2023 Jul; 43(7):1134-1153. PubMed ID: 37078287
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD301b/MGL2
    Meier LA; Auger JL; Engelson BJ; Cowan HM; Breed ER; Gonzalez-Torres MI; Boyer JD; Verma M; Marath A; Binstadt BA
    Circulation; 2018 Jun; 137(23):2478-2493. PubMed ID: 29386201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term miR-29b suppression reduces aneurysm formation in a Marfan mouse model.
    Okamura H; Emrich F; Trojan J; Chiu P; Dalal AR; Arakawa M; Sato T; Penov K; Koyano T; Pedroza A; Connolly AJ; Rabinovitch M; Alvira C; Fischbein MP
    Physiol Rep; 2017 Apr; 5(8):. PubMed ID: 28455451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of transforming growth factor-β signaling and extracellular matrix production in myxomatous mitral valves by angiotensin II receptor blockers.
    Geirsson A; Singh M; Ali R; Abbas H; Li W; Sanchez JA; Hashim S; Tellides G
    Circulation; 2012 Sep; 126(11 Suppl 1):S189-97. PubMed ID: 22965982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elastin fragmentation in atherosclerotic mice leads to intraplaque neovascularization, plaque rupture, myocardial infarction, stroke, and sudden death.
    Van der Donckt C; Van Herck JL; Schrijvers DM; Vanhoutte G; Verhoye M; Blockx I; Van Der Linden A; Bauters D; Lijnen HR; Sluimer JC; Roth L; Van Hove CE; Fransen P; Knaapen MW; Hervent AS; De Keulenaer GW; Bult H; Martinet W; Herman AG; De Meyer GR
    Eur Heart J; 2015 May; 36(17):1049-58. PubMed ID: 24553721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Murine model of surgically induced acute aortic dissection type A.
    Matt P; Huso DL; Habashi J; Holm T; Doyle J; Schoenhoff F; Liu G; Black J; Van Eyk JE; Dietz HC
    J Thorac Cardiovasc Surg; 2010 Apr; 139(4):1041-7. PubMed ID: 19910001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PROX1 Inhibits PDGF-B Expression to Prevent Myxomatous Degeneration of Heart Valves.
    Ho YC; Geng X; O'Donnell A; Ibarrola J; Fernandez-Celis A; Varshney R; Subramani K; Azartash-Namin ZJ; Kim J; Silasi R; Wylie-Sears J; Alvandi Z; Chen L; Cha B; Chen H; Xia L; Zhou B; Lupu F; Burkhart HM; Aikawa E; Olson LE; Ahamed J; López-Andrés N; Bischoff J; Yutzey KE; Srinivasan RS
    Circ Res; 2023 Sep; 133(6):463-480. PubMed ID: 37555328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders.
    Attias D; Stheneur C; Roy C; Collod-Béroud G; Detaint D; Faivre L; Delrue MA; Cohen L; Francannet C; Béroud C; Claustres M; Iserin F; Khau Van Kien P; Lacombe D; Le Merrer M; Lyonnet S; Odent S; Plauchu H; Rio M; Rossi A; Sidi D; Steg PG; Ravaud P; Boileau C; Jondeau G
    Circulation; 2009 Dec; 120(25):2541-9. PubMed ID: 19996017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Developmental basis for filamin-A-associated myxomatous mitral valve disease.
    Sauls K; de Vlaming A; Harris BS; Williams K; Wessels A; Levine RA; Slaugenhaupt SA; Goodwin RL; Pavone LM; Merot J; Schott JJ; Le Tourneau T; Dix T; Jesinkey S; Feng Y; Walsh C; Zhou B; Baldwin S; Markwald RR; Norris RA
    Cardiovasc Res; 2012 Oct; 96(1):109-19. PubMed ID: 22843703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anatomically specific reactive oxygen species production participates in Marfan syndrome aneurysm formation.
    Emrich F; Penov K; Arakawa M; Dhablania N; Burdon G; Pedroza AJ; Koyano TK; Kim YM; Raaz U; Connolly AJ; Iosef C; Fischbein MP
    J Cell Mol Med; 2019 Oct; 23(10):7000-7009. PubMed ID: 31402541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transforming Growth Factor β Receptor Type I Inhibitor, Galunisertib, Has No Beneficial Effects on Aneurysmal Pathological Changes in Marfan Mice.
    Park JH; Kim MS; Ham S; Park ES; Kim KL; Suh W
    Biomol Ther (Seoul); 2020 Jan; 28(1):98-103. PubMed ID: 31284709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of Transforming Growth Factor-β Signaling in Myxomatous Mitral Valve Degeneration.
    Tang Q; McNair AJ; Phadwal K; Macrae VE; Corcoran BM
    Front Cardiovasc Med; 2022; 9():872288. PubMed ID: 35656405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased Infiltration of Extra-Cardiac Cells in Myxomatous Valve Disease.
    Sauls K; Toomer K; Williams K; Johnson AJ; Markwald RR; Hajdu Z; Norris RA
    J Cardiovasc Dev Dis; 2015 Sep; 2(3):200-213. PubMed ID: 26473162
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of β-arrestin2-dependent signaling in thoracic aortic aneurysm formation in a murine model of Marfan syndrome.
    Wisler JW; Harris EM; Raisch M; Mao L; Kim J; Rockman HA; Lefkowitz RJ
    Am J Physiol Heart Circ Physiol; 2015 Nov; 309(9):H1516-27. PubMed ID: 26371162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autocrine serotonin and transforming growth factor beta 1 signaling mediates spontaneous myxomatous mitral valve disease.
    Disatian S; Orton EC
    J Heart Valve Dis; 2009 Jan; 18(1):44-51. PubMed ID: 19301552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.